PMID- 20081258
OWN - NLM
STAT- MEDLINE
DCOM- 20100330
LR  - 20200106
IS  - 2299-5684 (Electronic)
IS  - 1734-1140 (Linking)
VI  - 61
IP  - 6
DP  - 2009 Nov-Dec
TI  - Effect of peptide and nonpeptide antagonists of angiotensin II receptors on 
      noradrenaline release in hypothalamus of rats with angiotensin II-induced 
      increase of water intake.
PG  - 1206-10
AB  - Angiotensin II (Ang II) administered intracerebroventriculary (icv) at a dose 
      that induces drinking behavior in rats significantly increased K(+)-stimulated 
      release of [(3)H] noradrenaline (NA) in hypothalamus without affecting basal 
      [(3)H] NA release. The observed difference between the effects of Ang II on basal 
      and K(+)-stimulated [(3)H]NA release may possibly be due to the fact that 
      peptides are released after increased neuronal activity. It can be suggested that 
      Ang II is important primarily in pathological states and that NA plays a 
      substantial role in the brain Ang II-induced drinking response. The imidazolic 
      nonpeptidic compound 
      2-n-butyl-4-chloro-5-hydroxymethyl-1-[2-(1H-tetrazol-5-yl)biphenyl-4-yl]methylimidazole 
      potassium salt (DuP 753, losartan), its active metabolite 
      2-n-butyl-4-chloro-1-[2-(1H-tetrazol-5-yl)- 
      biphenyl-4-yl]methylimidazole-5-carboxylic acid (EXP 3174) and peptide Ang II 
      analogue, sarmesin, antagonized the Ang II-induced effect on [(3)H]NA release, in 
      spite of the differences in their chemical structures. Thus, the drugs tested 
      inhibited K(+)-stimulated [(3)H]NA release in hypothalamus, acting via the 
      angiotensin (AT)(1) receptor subtype. We could not reject the possibility of a 
      non-receptor mechanism of action for DuP753, EXP3174 and sarmesin. This research 
      allows us to suggest a neurochemical mechanism for the modulatory role of these 
      drugs on the NA-ergic system. The Ang II receptor antagonists studied may become 
      important therapeutic agents, which act preferentially on pathologically 
      activated systems. These agents may be of use for the prevention of excessive 
      ingestion of water in some neuropsychotic diseases.
FAU - Stancheva, Stefanka
AU  - Stancheva S
AD  - Radioisotope Laboratory, Institute of Neurobiology, Bulgarian Academy of 
      Sciences, Acad. G. Bonchev 23, 1113 Sofia, Bulgaria. fany@bio.bas.bg
FAU - Alova, Liana
AU  - Alova L
FAU - Stefanova, Miroslava
AU  - Stefanova M
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Pharmacol Rep
JT  - Pharmacological reports : PR
JID - 101234999
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Imidazoles)
RN  - 0 (Receptor, Angiotensin, Type 1)
RN  - 0 (Tetrazoles)
RN  - 11128-99-7 (Angiotensin II)
RN  - 88874-29-7 (angiotensin II, Sar(1)-Me-Tyr(4)-)
RN  - GD76OCH73X (losartan carboxylic acid)
RN  - JMS50MPO89 (Losartan)
RN  - RWP5GA015D (Potassium)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - Angiotensin II/analogs & derivatives/metabolism/*pharmacology
MH  - Angiotensin II Type 1 Receptor Blockers/pharmacology
MH  - *Angiotensin Receptor Antagonists
MH  - Animals
MH  - Drinking/drug effects
MH  - Hypothalamus/drug effects/metabolism
MH  - Imidazoles/pharmacology
MH  - Injections, Intraventricular
MH  - Losartan/pharmacology
MH  - Male
MH  - Norepinephrine/*metabolism
MH  - Potassium/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Receptor, Angiotensin, Type 1/*drug effects/metabolism
MH  - Tetrazoles/pharmacology
EDAT- 2010/01/19 06:00
MHDA- 2010/03/31 06:00
CRDT- 2010/01/19 06:00
PHST- 2009/03/12 00:00 [received]
PHST- 2009/10/30 00:00 [revised]
PHST- 2010/01/19 06:00 [entrez]
PHST- 2010/01/19 06:00 [pubmed]
PHST- 2010/03/31 06:00 [medline]
AID - S1734-1140(09)70185-9 [pii]
AID - 10.1016/s1734-1140(09)70185-9 [doi]
PST - ppublish
SO  - Pharmacol Rep. 2009 Nov-Dec;61(6):1206-10. doi: 10.1016/s1734-1140(09)70185-9.